The Catalyst

Most Recent Posts


The other night, I watched a new police procedural on television. While the ultimate "bad guy" was a murderer who was part of a love triangle, at least one nefarious character under suspicion for the crime was a drug company scientist.

07.10.12 | By Greg Lopes

The Supreme Court has ruled, it's the middle of summer, and many people are on vacation and not focusing on healthcare, but I've been thinking about access and adherence to prescription medicines.

07.03.12 | By Greg Lopes

What if we had stopped innovating after discovering aspirin? Certainly we wouldn't have had the dramatic improvements in health outcomes that we've seen over the last hundred years. Over the years, medicines have played a key role in significantly reducing deaths, with major advances in treatments for heart disease, many cancers, and HIV/AIDS.

06.28.12 | By Greg Lopes

I'm excited to announce the launch of a new page on our Web site, "The Value of Medicines: Hope for Patients, Savings for the System." On this page, it is our intent to bring to your attention, in an easily digestible way, literature and research that examine the impact medicines have on patients' lives and to what extent improved health outcomes can affect health care costs.

It seems there are two fundamental questions around health care:

06.26.12 | By Greg Lopes

Over the years, I've learned that going to the pharmacy is not like a trip to the dentist - it's much less painful, and I'm always struck by how much pharmacists know and are willing to help. (Dentists are willing to help, but they often use a drill.)


Over the last several weeks, we've been fortunate to feature many blog posts on the Catalyst from prominent oncology researchers working for biopharmaceutical research companies. Many of these researchers have been active participants at various oncology conferences and events, such as the recent American Society of Clinical Oncology (ASCO) annual meeting, throughout the month of June. As these events wind down, we at PhRMA continue to reflect on progress that has been made in the war against cancer.


There has been a steady stream of media coverage out of last week's BIO meeting in Boston, Mass., highlighting the evolving biopharmaceutical research and development (R&D) model, particularly

06.22.12 | By Greg Lopes

It's time to talk about the other side of the issue when it comes to copay coupons. This is a pretty simple issue from my perspective, it's about getting patients the medicines they need.


As we march slowly toward an economic rebound, a new study predicts that 5.6 million new healthcare jobs will be created in America by 2020. The report was released by the Georgetown University Center for Education and the Workforce.

06.21.12 | By Kaelan Hollon

Today we have a guest post from Emily Skor, Vice President of Communications and Alliance Development for the Consumer Healthcare Products Association.

06.19.12 | By Greg Lopes

A Reuters article I read recently raises important issues about the cost of cancer care. But it missed an important theme: New treatments are changing and improving the way we treat cancer and while it's important to keep an eye on healthcare costs, we must see the bigger picture, which is the potential of new medicines.

06.14.12 | By Preet Bilinski

We sat down with Michael Sapienza, the Executive Director and Founder of Chris4Life, a patient advocacy organization committed to improving the treatment experience for patients and caregivers, and to dramatically raising awareness about colon cancer.

Q: How did Chris4Life get started?


Today we have a guest post from Dr. Salvatore Giorgianni, who is an expert in men's health and a pharmacist. He is an advisor and board member for Men's Health Network and serves as Chair-elect of the American Public Health Association Men's Health Caucus.

06.13.12 | By Kate Connors

Continuing on the theme of progress - and the ongoing work of researchers - in battling cancer, today I'd like to point out "Fighting Cancer: Don't Let Our Progress Slow," a column by our president and CEO John J. Castellani that the Huffington Post published yesterday.